Mein Warenkorb

Sortilin

Sortilin Molekülinformation

Englischer NameSortilinAnzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel3Target-Alias100 kDa NT receptor,NT3,Glycoprotein 95,LDLCQ6,NTR3,Gp95,Sortilin 1,Neurotensin receptor 3
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameSortilin
Target-Alias100 kDa NT receptor,NT3,Glycoprotein 95,LDLCQ6,NTR3,Gp95,Sortilin 1,Neurotensin receptor 3
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel3
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

Sortilin Produktliste

  • Attribut

    Protein (5)Cell (1)

  • Produktbibliothek

    Online (6)

  • Spezies

    Human (3)Cynomolgus (1)Rat (1)Canine (1)

  • Etikett

    His Tag (4)His Tag & Avi Tag (1)- (1)

  • Marker

    Unconjugated (4)Biotin-labeled (1)- (1)

Sortilin Molekülhintergrund

The Sortilin is a sorting receptor in the Golgi compartment and as a clearance receptor on the cell surface. Required for protein transport from the Golgi apparatus to the lysosomes by a pathway that is independent of the mannose-6-phosphate receptor (M6PR). Lysosomal proteins bind specifically to the receptor in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelysosomal compartment where the low pH mediates the dissociation of the complex. The receptor is then recycled back to the Golgi for another round of trafficking through its binding to the retromer.

Sortilin Molekülalias

Sortilin,SORT1,100 kDa NT receptor,Glycoprotein 95,Gp95,Gp95LDLCQ6,Neurotensin receptor 3,NT3NTR3,Ntr3,sortilin 1,

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
VES-001VES001; VES-001Phase 2 ClinicalVesper Bio APSDementia; Frontotemporal Dementia; Frontotemporal Lobar Degeneration
Details
LatozinemabAL-001; GSK-4527223Phase 1 ClinicalAlector Inc, Glaxosmithkline PlcAmyotrophic Lateral Sclerosis; Frontotemporal Dementia; Neurodegenerative Diseases
Details
ARB-1-6ARB-1-6; PQ-203Phase 1 ClinicalProteinQure IncBreast Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns